Literature DB >> 35125470

Optimal Lung Cancer Screening Criteria Among Persons Living With HIV.

Subhashini A Sellers1, Andrew Edmonds2, Catalina Ramirez3, Sushma K Cribbs4,5, Igho Ofotokun6, Laurence Huang7, Alison Morris8, Meredith C Mccormack9, Ken M Kunisaki10,11, Gypsyamber D'souza12, M Patricia Rivera1, M Bradley Drummond1, Adaora A Adimora3.   

Abstract

BACKGROUND: The US Preventive Services Task Force (USPSTF) 2021 updated recommendations on lung cancer screening with chest computed tomography to apply to individuals 50-80 years of age (previously 55-80 years), with a ≥20 pack-year history (previously ≥30), whether currently smoking or quit ≤15 years ago. Despite being at higher risk for lung cancer, persons with HIV (PWH) were not well-represented in the National Lung Screening Trial, which informed the USPSTF 2013 recommendations. It is unknown or unclear how PWH are affected by the 2021 recommendations.
SETTING: This study was a retrospective analysis of PWH with and without lung cancer in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
METHODS: We identified PWH, ages 40-80 years, who currently or previously smoked, with (cases) and without lung cancer (noncases). The sensitivity and specificity of the old, new, and alternative screening criteria were evaluated in each cohort.
RESULTS: We identified 52 women and 19 men with lung cancer and 1950 women and 1599 men without lung cancer. Only 11 women (22%) and 6 men (32%) with lung cancer met 2013 screening criteria; however, more women (22; 44%) and men (12; 63%) met 2021 criteria. Decreased age and tobacco exposure thresholds in women further increased sensitivity of the 2021 criteria.
CONCLUSIONS: The 2021 USPSTF lung cancer screening recommendations would have resulted in more PWH with lung cancer being eligible for screening at the time of their diagnosis. Further investigation is needed to determine optimal screening criteria for PWH, particularly in women.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35125470      PMCID: PMC9203877          DOI: 10.1097/QAI.0000000000002930

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  43 in total

1.  HIV as an independent risk factor for incident lung cancer.

Authors:  Keith Sigel; Juan Wisnivesky; Kirsha Gordon; Robert Dubrow; Amy Justice; Sheldon T Brown; Joseph Goulet; Adeel A Butt; Stephen Crystal; David Rimland; Maria Rodriguez-Barradas; Cynthia Gibert; Lesley S Park; Kristina Crothers
Journal:  AIDS       Date:  2012-05-15       Impact factor: 4.177

Review 2.  Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. preventive services task force.

Authors:  Christopher G Slatore; Christina Baumann; Miranda Pappas; Linda L Humphrey
Journal:  Ann Am Thorac Soc       Date:  2014-05

Review 3.  HIV infection in the etiology of lung cancer: confounding, causality, and consequences.

Authors:  Gregory D Kirk; Christian A Merlo
Journal:  Proc Am Thorac Soc       Date:  2011-06

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort.

Authors:  A Makinson; L Tron; S Grabar; B Milleron; J Reynes; V Le Moing; D Morquin; F Lert; D Costagliola; M Guiguet
Journal:  HIV Med       Date:  2019-11-15       Impact factor: 3.180

6.  Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.

Authors:  Ard I van Sighem; Luuk A J Gras; Peter Reiss; Kees Brinkman; Frank de Wolf
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

7.  HIV infection is associated with an increased risk for lung cancer, independent of smoking.

Authors:  Gregory D Kirk; Christian Merlo; Peter O' Driscoll; Shruti H Mehta; Noya Galai; David Vlahov; Jonathan Samet; Eric A Engels
Journal:  Clin Infect Dis       Date:  2007-05-22       Impact factor: 9.079

8.  Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers.

Authors:  Alain Makinson; Sabrina Eymard-Duvernay; François Raffi; Sophie Abgrall; Sébastien Bommart; David Zucman; Florent Valour; Antoine Cheret; Isabelle Poizot-Martin; Claudine Duvivier; Jean-Marc Mauboussin; Fabrice Bonnet; Pierre Tattevin; Jacques Reynes; Vincent Le Moing
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

9.  Cohort Profile: The Women's Interagency HIV Study (WIHS).

Authors:  Adaora A Adimora; Catalina Ramirez; Lorie Benning; Ruth M Greenblatt; Mirjam-Colette Kempf; Phyllis C Tien; Seble G Kassaye; Kathryn Anastos; Mardge Cohen; Howard Minkoff; Gina Wingood; Igho Ofotokun; Margaret A Fischl; Stephen Gange
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

10.  Comparison of two screening tests for HIV-Associated Neurocognitive Disorder suspected Japanese patients with respect to cART usage.

Authors:  Kaoru Kami-Onaga; Masao Tateyama; Takeshi Kinjo; Gretchen Parrott; Daisuke Tominaga; Ai Takahashi-Nakazato; Hideta Nakamura; Daisuke Tasato; Kyoko Miyagi; Saori Maeda; Hirotaka Arae; Hitoshi Uehara; Kazuya Miyagi; Shusaku Haranaga; Jiro Fujita
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

View more
  1 in total

1.  Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees.

Authors:  Zi-Hao Chen; Zhi-Yong Chen; Jing Kang; Xiang-Peng Chu; Rui Fu; Jia-Tao Zhang; Yi-Fan Qi; Jing-Hua Chen; Jun-Tao Lin; Ben-Yuan Jiang; Xue-Ning Yang; Yi-Long Wu; Wen-Zhao Zhong; Qiang Nie
Journal:  Thorac Cancer       Date:  2022-07-11       Impact factor: 3.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.